The 2026 State of Growth Stacks.
We surveyed 340 growth and CRO leaders at Series A–C companies between October 2025 and February 2026. The results are ugly, candid, and extremely actionable. Every benchmark is sourced; every anecdote is anonymized.
Get the full report.
One email. No drip, no sales outreach unless you ask. The PDF hits your inbox in 30 seconds.
Already a customer? The report is in your Flight Deck resources tab.
Five chapters. Forty-eight pages.
Stack composition
What Series A, B, and C teams actually run. The median stack has 6.2 tools. The 90th percentile has 11. We break down who uses what at each stage.
Spend benchmarks
By stage, company size, and vertical. What the top quartile spends vs. the bottom. Why most teams are overpaying for testing infrastructure they don't use.
Testing velocity
The top 10% of teams ship 6–8 tests per quarter. The median ships 2. We map the operational patterns that differentiate the fast ones.
Tool overlap
Where your tools are doing the same job. The average team pays twice for competitor monitoring, three times for SEO rank tracking, and once each for four different analytics backbones.
The consolidation playbook
How the 47 companies in our sample that consolidated did it. What stayed, what went, and the 12-month impact on testing velocity and revenue per experiment.
How we collected the data.
Sample
340 growth and CRO leaders at Series A–C companies (11–500 employees), collected Oct 2025 – Feb 2026 via partner VCs, LinkedIn outreach, and the Optimize Pilot customer base.
Distribution
Weighted to match the US SaaS funding distribution: ~55% Series A, ~30% Series B, ~15% Series C. Vertical skew: SaaS, FinTech, E-commerce, DTC.
Verification
Tool spend cross-referenced with billing data for ~60% of respondents (voluntary). Testing velocity triangulated from Optimizely / VWO export data where available.
Limitations
US / UK only. Excluded pre-Series A. Excluded teams with zero digital product. If you ran the same study on bootstrapped SaaS, the numbers would be half.
Benchmarks are nice. Moving numbers is better.
The report tells you where you stand. The 14-day trial tells you what to do about it.